Treatment-Resistant Depression Market Growth Analysis By DelveInsight
Treatment-resistant depression (TRD) is a major depressive disorder (MDD) that does not respond adequately to a course of appropriate antidepressant medication within a certain time. MDD is a mood disorder that causes a persistent feeling of sadness and loss of interest, which can interfere with day-to-day life. Depression lasting at least 2 weeks along with meeting about five or more of the DSM-V criteria (of MDD) is considered as MDD. Further, those with at least one episode in the prior 12 months are classified as 12-month MDD.
Treatment-Resistant Depression Market Key Facts
- Among the 7MM, the US accounts for 81% of the overall Treatment-Resistant Depression (TRD) market size in 2017, and in the EU-5 countries, the UK accounts for the highest market size for Treatment-Resistant Depression (TRD) followed by Germany, France, Spain, and Italy.
- The total diagnosed prevalent population of Treatment-Resistant Depression in 7MM countries estimated to be 4,464,781 cases in 2017.
- In 2017, the prevalence of TRD in the US was highest with 3,083,238 cases which are estimated to increase in the forecasted period.
- Among the European countries, UK had the highest population of Treatment-Resistant Depression with 570,565 cases, followed by Germany which had 233,432 in 2017. While Italy had the lowest prevalent population of 45,641 cases in 2017.
DelveInsight's "Treatment-Resistant Depression Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Treatment-Resistant Depression market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Treatment-Resistant Depression Market Analysis
DelveInsight’s analysts estimate that the market is expected to show positive growth, mainly attributed to an increased number of cases and the expected launch of the emerging therapies.
The Treatment-Resistant Depression market analysis section of the report helps to understand the current and forecasted Treatment-Resistant Depression market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Treatment-Resistant Depression market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Treatment-Resistant Depression (TRD) Therapeutics Market
To fulfill the current unmet need, there is hope that biomarkers will be found to guide treatment selection. Currently, however, there is not enough evidence to justify routine genotyping for patients with TRD. Pharmacogenetic testing for genetic variants of metabolizing enzymes may be considered for patients who do not respond to pharmacotherapy.
Some of the key Treatment-Resistant Depression (TRD) Companies actively involved in the development of therapies include Allergan, Alkermes, Allergan, Novartis, Celon Pharma, Gedeon Richter’s, VistaGen Therapeutics, Relmada Therapeutics, COMPASS Pathways, Johnson and Johnson, Minerva Neurosciences, Axsome Therapeutics, ACADIA Pharmaceuticals, VistaGen Therapeutics, and others. Treatment-Resistant Depression (TRD) Therapies covered in the report include REL-1017, AV-101, MIJ821, ALKS 5461, Cariprazine, Pimavanserin, AXS-05, Seltorexant, Rapastinel, Esketamine DPI, PH10 Nasal Spray, Psilocybin (COMP360), and many more.
Treatment-Resistant Depression (TRD) Market Drivers
- Refined Clinical Trial Design
- Development of pioneering therapies
- Retainment of Current management strategies
Treatment-Resistant Depression (TRD) Market Barriers
- Variable Treatment Response
- Commercial Challenges
Treatment-Resistant Depression (TRD) Epidemiology Segmentation
- Total Diagnosed Prevalent cases of Treatment Resistant Depression
- Gender-specific cases of Treatment Resistant Depression
- Age-specific cases of Treatment Resistant Depression
Treatment-Resistant Depression Epidemiology Forecast
The Treatment-Resistant Depression epidemiology section covers insights about historical and current Treatment-Resistant Depression patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Treatment-Resistant Depression Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Treatment-Resistant Depression Market Growth